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In this cross-sectional study of 42 solid organ transplant recipients, the association of human cytomegalovirus
(HCMV) replication and age with the phenotype of the HCMV-specific CD8 T cells was analyzed by using the
CMV pp65 HLA-A*0201 pentamer. A correlation between the proportion of CD28 HCMV-specific CD8 T cells
and age was observed in patients without HCMV replication (r  0.50; P  0.02) but not in patients with HCMV
replication (r  0.05; P  0.83), a finding which differs from that observed for total CD8 T cells. Within the group
of patients younger than 50 years of age, patients with HCVM replication after transplantation had higher
percentages of CD28 HCMV-specific CD8 T cells (85.6 compared with 58.7% for patients without HCMV
replication; P  0.004) and CD27 HCMV-specific CD8 T cells (90.7 compared with 68.8% for patients without
HCMV replication; P  0.03). However, in patients older than age 50 years, a high frequency of these two
subpopulations was observed in patients both with and without previous HCMV replication (for CD28 HCMV-
specific CD8 T cells, 84.4 and 80.9%, respectively [P  0.39]; for CD27 HCMV-specific CD8 T cells 86.6 and
81.5%, respectively [P  0.16]). In conclusion, the present study shows that in the group of recipients younger than
age 50 years, HCMV replication after transplantation is associated with a high percentage of CD27 and CD28
HCMV-specific CD8 T cells. These results suggest that the increased percentage of CD27 or CD28 HCMV-
specific subsets can be considered a biomarker of HCMV replication in solid organ transplant recipients younger
than age 50 years but not in older patients. Further studies are necessary to define the significance of these changes
in HCMV-associated clinical complications posttransplantation.
Although a robust innate immune response is quickly in-
duced just after the entry of human cytomegalovirus (HCMV)
(21), the adaptive response of CD8 T cells plays a major role
in the control of HCMV infection (9, 19, 36). The development
of HLA multimer technology and the analysis of surface mark-
ers (CD45RA, CCR7, CD27, CD28) have allowed the study of
the CMV-specific CD8 T-cell immune response and its phe-
notypic characteristics. Naïve cells (CD45RA CCR7), which
lose the ability to express CD45RA after interaction with the
antigen, become memory cells and comprise two subpopula-
tions: central memory cells (CD45RA CCR7) and effector
memory cells (CD45RA CCR7). Subsequently, a fraction of
the HCMV-specific effector memory cells may revert to RA
expression (CD45RA CCR7) after the acute phase of in-
fection (32, 34). CD28 and CD27 costimulatory molecules,
however, are also useful markers in determining the phenotype
of CD8 T cells and allow their classification into early mem-
ory cells (CD27 CD28), intermediate memory cells (CD27
CD28), and late memory cells (CD27 CD28), which pro-
gressively increase their levels of perforin production (3, 32).
Latent HCMV infection is associated with the massive
clonal expansion of virus-specific memory CD8 T cells (47),
which is especially pronounced in HCMV-seropositive elderly
patients. In these patients, the population of HCMV-specific
CD8 T cells shows a highly differentiated phenotype with a
high percentage of CD28 lymphocytes and a series of func-
tional changes associated with a process of immune senes-
cence. It has been suggested that HCMV may contribute sig-
nificantly to this senescence process (29, 33, 45, 50). In fact, the
combination of HCMV seropositivity with a high percentage of
CD28 cells and inversion of the CD4/CD8 ratio define the
so-called immune risk phenotype, which some longitudinal
studies have associated with decreased survival in individuals
older than 80 years of age (1, 23, 24, 29, 53).
Because of immunosuppression, there is a higher frequency
of CMV reactivation in CMV-seropositive transplant recipi-
ents and of primary infection in CMV-seronegative recipients
receiving a CMV-seropositive organ (donor positive and recip-
ient negative [D/R] patients) (13–15). HCMV replication
may induce the accumulation of HCMV-specific CD8 T cells
observed in some studies, which may account for as much as 10
to 50% of the total CD8 T-cell pool (26, 27). Furthermore,
other studies show that these cell clones may have a highly
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differentiated phenotype (5, 6, 18) and may show functional
changes similar to those observed in HCMV-seropositive el-
derly individuals (10, 17, 26). These observations led us to
propose the hypothesis that transplant patients with HCMV
replication after transplantation may have a population of
HCMV-specific CD8 T cells with a more differentiated phe-
notype and a higher percentage of CD28 and/or CD27 cells
than transplant patients without replication. In order to test
this hypothesis, a cross-sectional study was carried out with
patients who had received a solid organ transplant at least 1
year earlier to determine the frequency and phenotype of the
HCVM-specific CD8 T-cell population and its relationship to
age and HCMV replication posttransplantation.
MATERIALS AND METHODS
Study population and design. The study was carried out at a single center
(Reina Sofia University Hospital, Córdoba, Spain). From October 2007 to April
2008, 42 patients who had undergone a transplant (n  12 lung transplants, n 
30 kidney transplants) at least 1 year earlier were included in the study. All
patients had the HLA-A*02 allele and correct posttransplantation monitoring
for HCMV replication. Monitoring for HCMV replication was considered to be
correct when the HCMV load was determined at least weekly during the hospi-
talization, at least every 2 weeks until the third month, and monthly until the first
year. The patients studied received the transplants between March 2005 and
November 2006. To prevent HCMV replication, preemptive therapy was used
when evidence of asymptomatic HCMV infection was detected by PCR, and
universal prophylaxis was administered only to individuals at high risk, such as
D/R patients, recipients receiving antilymphocyte therapy, and lung recipi-
ents. The study was approved by the ethics committee of the Reina Sofia Uni-
versity Hospital.
Determination of anti-HCMV immunoglobulin G antibodies and HCMV load.
The presence of anti-HCMV immunoglobulin G antibodies pretransplantation
was determined for the donors and the recipients by chemoluminescence assay
(Diasorin SA).
The HCMV load was determined by quantitative PCR (Cobas Amplicor,
Roche). Viral DNA was isolated from citrate-anticoagulated whole-blood sam-
ples, according to the manufacturer’s instructions. The detection limit of this test
is 400 genomes/ml, so values above this limit were considered positive viral loads.
Immunosuppression and prevention of HCMV infection. Initial immunosup-
pression consisted of cyclosporine-tacrolimus combined with mofetil mycophe-
nolate-azathioprine and steroids. Episodes of acute rejection were treated with
steroid boluses or recycling of steroid tapers. Lung transplant patients received
prophylaxis with intravenous ganciclovir (5 mg/kg of body weight/day)-valganci-
clovir (900 mg/day) for 6 months. Kidney transplant patients received preemptive
therapy (900 mg/12 h) or universal prophylaxis (900 mg/day) with valganciclovir
for 3 months. Episodes of viral replication were treated for at least 2 weeks or
until the PCR result was negative.
Isolation of mononuclear cells from peripheral blood. Peripheral blood mono-
nuclear cells (PBMCs) were obtained from 20 ml of peripheral whole blood in
tubes with acid-citrate-dextrose by Ficoll-Histopaque density gradient centrifu-
gation. Purified PBMCs were cryopreserved at 80°C in fetal calf serum con-
taining 10% dimethyl sulfoxide. PBMCs were obtained during routine follow-up
visits posttransplantation. No evidence of acute HCMV infection at the time of
PBMC extraction was found.
Study of HCMV-specific CD8 T-cell population. The PBMC samples were
thawed in a 37°C water bath; and the lymphocytes were centrifuged at 1,800 rpm
for 5 min or until a pellet was obtained, resuspended in phosphate-buffered
saline, counted, and aliquoted at approximately 500,000 cells per tube.
For the study of the HCMV-specific CD8 T-cell population, an HLA-A*0201
pentamer bound to an immunodominant epitope of HCMV (pp65, NLVPMV
ATV) labeled with allophycocyanin (Proimmune) was used. Although the anal-
ysis of virus-specific T cells with multimers is limited by the allele and the peptide
used, no differences in the phenotype or function of multimer-positive cells
depending on the HLA allele considered have been reported. Thus, the findings
obtained with HLA-A2 pentamers can be generalized to other virus-specific CD8
populations (3, 26). The cells were incubated with 10 l of the pentamer for 10
min at room temperature in the dark. The cells were then washed in MACS
buffer (bovine serum albumin supplemented with EDTA) and incubated with
anti-CD8 monoclonal antibodies labeled with peridinin chlorophyll protein (Bec-
ton Dickinson) and monoclonal antibodies against other surface molecules
(CD45RA, CCR7, CD28, CD27) labeled with phycoerythrin and fluorescein
isothiocyanate (FITC; Becton Dickinson) for 30 min on ice in the dark. Intra-
cellular perforin and granzyme B staining was performed by incubating the
PBMCs with fluorescence-labeled conjugated monoclonal antibodies to CD8
(Becton Dickinson) and HCMV-pentamer complexes. The PBMCs were washed
once, fixed, and subsequently permeabilized by using an IntraStain kit (Dako
Cytomation), according to the manufacturer’s instructions. The cells were then
incubated with antiperforin (FITC) and anti-granzyme B (FITC), as indicated
above. Analysis of the cells was performed with a four-color FACSCalibur flow
cytometer and Cellquest software (Becton Dickinson).
Statistical analysis. Statistical analysis was performed by using the SPSS (ver-
sion 15.0) program. The total population of CD8 T cells was counted and
expressed as a proportion of the total lymphocytes, and the population of
HCMV-specific CD8 T cells was counted and expressed as a proportion of the
total population of CD8 T cells. Determination of whether there was a corre-
lation between age and the percentage of lymphocyte subpopulations was carried
out by using the nonparametric Spearman rank correlation test. Comparison of
the percentages of different subpopulations among the different groups was
carried out by using the Mann-Whitney U test. In this case, patients were
stratified according to age into two groups: those older than 50 years of age and
those younger than 50 years of age. Univariate and multivariate linear regression
analyses were used to identify the variables associated with the CD27/CD28
HCMV-specific CD8 T-cell percentages. The following variables were included
in the analyses: donor-recipient HCMV serostatus (D/R or R), HCMV
replication (negative or positive) posttransplantation, age (younger and older
than 50 years), and the organ transplanted (kidney or lung). Values were con-
sidered statistically significant when the P value was 0.05.
RESULTS
Demographic data. Forty-two patients (30 men, 12 women)
who had the HLA-A*02 allele were studied. The median age
of the group was 46.5 years (age range, 15 to 75 years). Twenty-
six patients were younger than 50 years of age, and 16 patients
were over that age. The demographic characteristics of these
groups are indicated in Table 1.
TABLE 1. Demographic characteristics of the study population
Characteristic
Value for patients with ages of:
50 yr 50 yr
Total no. of patients 26 16
No. (%) patients of the following sex:
Male 19 11
Female 7 5
Median (range) age (yr) 34.5 (15–49) 60 (52–75)
Median (range) time of follow-up (days) 935 (418–1,105) 666 (436–1,018)
No. (%) of patients with the following
organ transplant:
Renal 16 (61.5) 14 (87.5)
Lung 10 (38.5) 2 (12.5)







No. of patients receiving antiviral
treatment
Preemptive therapy 12 12
Universal prophylaxis 14 4
No. (%) of patients with the following
HCMV serostatus:
R 19 (73.1) 14 (87.5)
D/R 7 (26.9) 2 (12.5)
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Frequency of HCMV-specific CD8 T cells determined by
use of HLA pentamer. Figure 1 shows the representative re-
sults of a plot analysis of HCMV-specific CD8 T cells per-
formed with the HLA-A*02 pentamer from four transplant
recipients, according to the donor and the recipient HCMV
serostatus and HCMV replication. No significant differences in
the frequency of HCMV-specific CD8 T cells were observed
when the patients were compared by age (older or younger
than 50 years) or the presence of HCMV replication episodes
after transplantation (data not shown).
Quantification of CD28 and CD27 lymphocyte subpopu-
lations in total CD8 T cells. The median percentage of total
CD8 T cells was 20.18% (range, 5.02 to 43.39%), and no
significant differences were observed between patients with
and without replication in the group younger than age 50 years
(22.21% [range, 10.25 to 41.57%] and 20.05% [range, 5.02 to
40.58%], respectively; P  0.49) or the group older than age 50
years (19.53% [range, 9.23 to 43.39%] and 19.33% [range,
11.55 to 27.87%], respectively; P  0.74).
The proportion of CD28 total CD8 T cells (Fig. 2A)
increased with age, so that there was a linear correlation be-
tween these two parameters both in patients with HCMV rep-
lication (r  0.49; P  0.02) and in those with no replication
(r  0.44; P  0.05). This explains why the proportion of this
FIG. 1. Plots of pentamer-labeled HCMV-specific CD8 T cells from four representative transplant recipients. (A) HCMV D/R patient and
no HCMV replication (n  3; median, 0.41%; range, 0.30 to 0.60%); (B) HCMV D/R patient and HCMV replication (n  6, median%, 1.24;
range, 0.12 to 4.15%); (C) HCMV R patient and no HCMV replication (n  19, median%, 2.45; range, 0.14 to 22.00%); (D) HCMV R patient
and HCMV replication (n  14, median, 3.79%; range, 0.14 to 13.20%). Values indicate the percentage of pentamer-positive cells with reference
to the total number of CD8 T cells. n, number of patients for each situation; total number of patients, 42.
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lymphocyte subpopulation was significantly higher in patients
older than age 50 years than in those younger than age 50 years
both in patients with HCMV replication (79.3% [range, 41.1 to
93.6%] and 55.8% [range, 39.5 to 88.7%], respectively; P 
0.03) and in those with no replication (69.8% [range, 58.7 to
79.7%] versus 45.7% [range, 7.8 to 90.4%], respectively; P 
0.02) (Fig. 2C). However, no significant differences in the me-
dian percentage of CD28 total CD8 T cells were observed
between patients with and without HCMV replication in the
group of patients younger than age 50 years (55.8% and 45.7%,
respectively; P  0.20) or older than age 50 years (79.3% and
69.8%, respectively; P  0.07) (Fig. 2C).
With regard to the CD27 marker, in patients without
HCMV replication, there was a trend toward a correlation
between the percentage of CD27 total CD8 T cells and age;
however, the difference was not statistically significant (r 
0.32; P  0.15) (Fig. 2B). The same result was observed when
the values were compared by age group, as the proportion of
CD27 total CD8 T cells in patients older than age 50 years
was not significantly higher than that in patients younger than
age 50 years without HCMV replication (66% [range, 57.94 to
90.03%] and 50.9% [range, 8.2 to 90.8], respectively; P  0.10)
(Fig. 2D). In patients with HCMV replication, however, there
was a statistically significant linear correlation between the
percentage of CD27 total CD8 T cells and age (r  0.51;
P  0.02) (Fig. 2B). This result was confirmed when the values
were compared by age group, as the percentage of CD27 total
CD8 T cells was significantly higher in patients older than age
50 years than in patients younger than age 50 years (79.2%
[range, 38.4 to 93.8] and 56.4% [range, 42.2 to 89.7], respec-
tively; P  0.02). No significant differences in the median
percentage of CD27 total CD8 T cells were observed be-
tween patients with and without HCMV replication in the
group of patients younger than age 50 years (56.4% and 50.9%,
respectively; P  0.37) and the group older than age 50 years
(79.4% and 66.0%, respectively; P  0.10) (Fig. 2D).
Quantification of CD28 and CD27 lymphocyte subpopu-
lations in HCMV-specific CD8 T cells. In patients without
HCMV replication, the percentage of CD28 HCMV-specific
CD8 T cells showed a linear correlation with age, so that the
older that the patient was, the higher the frequency of this
population became (r  0.50; P  0.02) (Fig. 3A). When the
same patients were compared by age group, patients older than
age 50 years had a significantly higher percentage of CD28
HCMV-specific CD8 T cells than patients younger than age
50 years (80.9% [range, 54.2 to 96.2%] and 58.7% [range, 8.7
FIG. 2. (A) Correlation between age and CD28 total CD8 T-cell percentage in patients with HCMV replication (F; linear regression, solid
line) and without HCMV replication (E; linear regression, dashed line). (B) The same analysis described for panel A for CD27 total CD8 T
cells. (C and D) Box plots for CD28 and CD27 total CD8 T-cell frequency, respectively, according to age (50 and 50 years) (open boxes,
patients without HCMV replication; shaded boxes, patients with HCMV replication). The median value of each data set is shown as a horizontal
line within the box, which encompasses the 25th and 75th percentiles. The whiskers extending from either end of the box represent the range of
the data.
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to 91.3%], respectively; P  0.047) (Fig. 3C). In patients with
HCVM replication, the correlation between age and the per-
centage of CD28 HCMV-specific CD8 T cells observed in
patients without replication was not observed (r  0.051; P 
0.83). In this group, all patients had more than 58% CD28
HCMV-specific CD8 T cells, regardless of their age, includ-
ing those transplant recipients between 18 and 30 years of age,
in whom 94 to 97% of HCMV-specific CD8 T cells were
CD28 (Fig. 3A). When patients showing HCMV replication
were compared by age, no significant differences in the per-
centage of CD28 HCMV-specific CD8 T cells were ob-
served between patients younger than or older than 50 years of
age (85.6% [range, 58.7 to 97.2%] and 84.4% [range, 73.8 to
97.6%], respectively; P  0.65) (Fig. 3C).
With regard to the CD27 marker, although there was a trend
toward a linear correlation between the percentage of CD27
HCMV-specific CD8 T cells and age in patients without viral
replication, it was not statistically significant (r  0.32; P 
0.14) (Fig. 3B). Similar results were observed when the same
patients were distributed into two age groups (those younger
than and those older than 50 years of age). Even though pa-
tients in the older subgroup without HCMV replication
showed an increase in the proportion of CD27 HCMV-spe-
cific CD8 T cells (81.5% [range, 54.9 to 97.0%] versus 68.8%
[range, 5.5 to 97.7%] for those in the younger subgroup; P 
0.16), the differences were not statistically significant (Fig. 3D).
The trend toward a correlation between the percentage of
CD27 HCMV-specific CD8 T cells and age observed in
patients without HCMV replication disappeared in patients
with virus replication, and all patients had a high percentage of
CD27 lymphocytes (over 60%), regardless of their age. As
with CD28, patients between 18 and 30 years of age had 92 to
97% CD27 HCMV-specific CD8 T cells (Fig. 3B). These
results were confirmed when the same values were analyzed by
age group, as no differences in the percentage of CD27
HCMV-specific CD8 T cells were observed between patients
younger than and older than 50 years of age (90.7% [range,
61.1 to 97.8%] and 86.6% [range, 77.8 to 97.8%], respectively;
P  0.60) (Fig. 3D).
When the percentages of CD27 and CD28 HCMV-spe-
FIG. 3. (A) Correlation between age and CD28 HCMV-specific CD8 T-cell percentage in patients with HCMV replication (F; linear
regression, solid line) and without HCMV replication (E; linear regression, dashed line). (B) The same analysis described for panel A for CD27
HCMV-specific CD8 T cells. (C and D) Box plots for CD28 and CD27 HCMV-specific CD8 T-cell frequency, respectively, according to age
(50 and 50 years) (open boxes, patients without HCMV replication; shaded boxes, patients with HCMV replication). HCMV-specific CD8
T-cell data are expressed as the proportion of total CD8 T cells. The median value of each data set is shown as a horizontal line within the box,
which encompasses the 25th and 75th percentiles. The whiskers extending from either end of the box represent the range of the data.
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cific CD8 T cells were analyzed separately in patients younger
than and older than age 50 years, no significant differences in
the percentage of CD28 HCMV-specific CD8 T cells were
found in the group of patients older than age 50 years with and
without HCMV replication (84.4% [range, 73.8 to 97.6%] and
80.9% [range, 54.2 to 96.2%], respectively; P  0.39), and no
significant differences in the percentage of CD27 HCMV-
specific CD8 T cells were found in the group of patients older
than age 50 years with and without HCMV replication (86.6%
[range, 77.8 to 97.8%] and 81.5% [range, 54.9 to 97.03%],
respectively; P  0.16). However, for the group of recipients
younger than age 50 years, when patients with HCMV repli-
cation were compared with patients without replication, pa-
tients with HCMV replication showed a significant increase in
the percentage of CD28 HCMV-specific CD8 T cells
(85.6% [range, 58.7 to 97.9%] and 58.7% [range, 8.7 to 91.3%],
respectively; P  0.004) and CD27 HCMV-specific CD8 T
cells (90.7% [range, 61.1 to 97.8%] and 68.8% [range, 5.8 to
97.7%], respectively; P  0.03) (Fig. 3C and 3D).
However, as shown in Table 2, despite the increase in the
percentages of CD27 and CD28 cells observed in patients
younger than age 50 years when the percentages were analyzed
separately, when both markers were analyzed together, the
CD27 CD28 lymphocyte population, defined as late-pheno-
type cells, showed no significant increase with replication in the
same group of patients (38.3% [range, 2.2 to 77.0%] and 60.2%
[range, 28.6 to 76.7%], respectively; P  0.10), possibly since
not all CD28 lymphocytes are CD27 but a certain propor-
tion of CD28 lymphocytes are CD27. It was precisely the
CD27 CD28 population, or intermediate-phenotype cells,
that increased significantly (7.6% [range, 1.4 to 38.4%] and
22.8% [range, 2.5 to 52.4], respectively; P  0.01) in patients
younger than age 50 years with HCMV replication, while a
parallel decrease was also observed in the most immature
population, or early-phenotype cells (CD27 CD28) (34.9%
[range, 5.4 to 91.7%] and 10.6% [range, 2.6 to 32.8%], respec-
tively; P  0.003).
Factors associated with the CD27/CD28 HCMV-specific
CD8 T cell percentages. A series of univariate and multivar-
iate linear regression models were used to determine the vari-
ables associated with the frequency of CD27 and CD28 cells
within the pool of HCMV-specific CD8 T cells (Table 3). The
univariate models showed that patients with HCMV replica-
tion had 23.27% more HCMV-specific CD8 CD28 cells
than patients without HCMV replication and that patients
older than age 50 years had 18.31% more HCMV-specific
CD8 CD28 cells than patients younger than age 50 years.
The analysis of the percentage of CD27 cells showed that
HCMV replication posttransplantation, age, and the type of
organ transplanted were associated with the percentage of
HCMV-specific CD8 CD27 cells. Thus, patients with
HCMV replication had 21.04% more HCMV-specific CD8
CD27 cells than patients without virus replication, patients
older than age 50 years had 16.00% more HCMV-specific
TABLE 2. Subpopulations of HCMV-specific CD8 T cells obtained on the basis of CD27 and CD28 receptor expression in patients with
and without HCMV replication according to agea
Subpopulation





No (n  16) Yes (n  10) No (n  6) Yes (n  10)
CD28 58.68 (8.67–91.30) 85.62 (58.73–97.92) 0.004 80.88 (54.24–96.25) 84.41 (73.83–97.60) 0.386
CD27 68.85 (5.48–97.74) 90.73 (61.06–97.79) 0.031 81.55 (54.87–97.00) 86.64 (77.78–97.80) 0.159
CD27 CD28 34.92 (5.40–91.67) 10.62 (2.65–32.76) 0.003 20.69 (2.25–32.56) 12.08 (0.81–24.17) 0.329
CD27 CD28 7.62 (1.39–38.39) 22.76 (2.46–52.40) 0.011 6.77 (2.33–54.92) 9.81 (5.98–21.67) 0.664
CD27 CD28 38.34 (2.25–76.97) 60.19 (28.60–76.75) 0.102 62.63 (11.69–94.00) 72.76 (53.33–90.65) 0.278
a The data are expressed as the median percentage (range).
TABLE 3. Linear regression analyses relating patient characteristics with the percentage of CD28 or CD27 HCMV-specific CD8 T cells
HCMV-specific CD8
T-cell type and patient
characteristica
Univariate analysis Multivariate analysisb
Mean difference in % of
cells (95% CIc) P
Mean difference in % of
cells (95% CI) P
CD28
HCMV serostatus 9.22 (8.77 to 27.21) 0.307
HCMV replication 23.27 (10.27 to 36.27) 0.001 20.22 (7.34 to 33.09) 0.003
Age 18.31 (4.06 to 32.56) 0.013 13.45 (0.21 to 26.69) 0.047
Organ transplanted 7.48 (23.86 to 8.90) 0.362
CD27
HCMV serostatus 15.87 (1.52 to 33.27) 0.072 21.84 (6.70 to 36.99) 0.006
HCMV replication 21.04 (7.76 to 34.32) 0.003 24.61 (12.17 to 37.05) 0.001
Age 16.00 (1.57 to 30.43) 0.031
Organ transplanted 18.15 (33.55 to 2.76) 0.022
a The patient characteristics are donor-recipient HCMV serostatus (D/R or R), HCMV replication (negative or positive) posttransplantation, age (younger and
older than 50 years), and type of organ transplanted (kidney or lung).
b In the multivariate analysis, only results with a P value of 0.05 after adjustment of the other variables are indicated.
c CI, confidence interval.
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CD8 CD27 cells than patients younger than age 50 years,
and patients who received a kidney transplant had 18.15%
more HCMV-specific CD8 CD27 cells than patients who
received a lung transplant.
The multivariate linear regression analysis demonstrated
that patients with HCMV replication had 20.22% more
HCMV-specific CD8 CD28 cells than patients without
HCMV replication and that patients older than age 50 years
had 13.45% more HCMV-specific CD8 CD28 cells than
patients younger than age 50 years, after adjustment for the
other variables. The analysis also showed that donor-recipient
HCMV serostatus and posttransplantation HCMV replication
were associated with the percentage of HCMV-specific CD8
CD27 cells. Thus, R patients had 21.84% more HCMV-
specific CD8 CD27 cells than D/R patients and patients
with HCMV replication had 24.61% more HCMV-specific
CD8 CD27 cells than patients without virus replication. Age
and the organ transplanted were not associated with the per-
centage of CD27 HCMV-specific CD8 T cells in the mul-
tivariate analysis.
Production of perforin and granzyme B by CD27 and
CD28 HCMV-specific CD8 T-cell subpopulations. With re-
gard to perforin production, it can be seen in Fig. 4 that there
was a linear correlation between the percentage of CD28
HCMV-specific CD8 T cells and the percentage of this cyto-
toxic molecule (r  0.62; P  0.001) (Fig. 4A). The same
correlation was observed with the percentage of CD27
HCMV-specific CD8 T cells (r  0.65; P  0.001) (Fig. 4B),
indicating that the greater that the proportion of cells with this
differentiated phenotype (CD28 or CD27) among HCMV-
specific CD8 T cells is, the greater that the level of produc-
tion of perforin becomes, which would imply a greater cyto-
toxic capacity of these subpopulations. On the contrary, no
correlation was observed between granzyme B (median,
2.13% [range, 0.01 to 78.68%]) and the percentages of
CD28 HCMV-specific CD8 T cells (r  0.27; P  0.90)
(Fig. 4C) or CD27 HCMV-specific CD8 T cells (r  0.19;
P  0.24) (Fig. 4D).
DISCUSSION
This study focused on the phenotype of HCMV-specific
CD8 T cells in kidney and lung transplant recipients accord-
ing to age and HCMV replication. The results showed a sta-
tistically significant association between HCMV replication
and the downregulation of CD27 and CD28 in recipients
younger than 50 years of age but not in older recipients.
The association between HCMV replication and a high per-
centage of CD27 T cells in younger individuals was observed
only for HCMV-specific CD8 T cells and not for total CD8
T cells, which rules out the idea that it is a general and non-
specific finding. The multivariate linear regression analysis in-
FIG. 4. Scatter plots showing correlations between percentages of CD28 and CD27 HCMV-specific CD8 T cells and the amounts of
perforin (A and B) and granzyme B (C and D) produced by these subpopulations. Spearman’s rank correlation test was used for statistical analysis;
a P value of 0.05 was considered significant.
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dicates that the main factors associated with the percentage
of HCMV-specific CD8 CD27 cells are donor-recipient
HCMV serostatus and posttransplantation HCMV replication
rather than age or the type of organ transplanted. These results
agree with those published previously that reported that
HCMV infection is associated with the loss of CD27 expression
(33) and that emphasized the correlation that exists between
the decreased frequency of CD27 expression and the increased
synthesis of cytotoxic molecules (perforin and granzymes) (3),
which were also observed in our patients. However, there is
certain controversy about the meaning of the loss of CD27
expression by CD8 T cells. Whereas some authors suggest
that they would correspond to effector cells with a high cyto-
lytic capacity and, therefore, with a certain protective action
(41, 46), other authors have associated the loss of CD27 ex-
pression with decreased proliferative capacity and immunose-
nescence (5, 28). We think that the loss of CD27 expression
observed in younger patients (those younger than age 50 years)
with prior HCMV replication may be a consequence of their
immune system’s effort to control the infection, while that
observed in patients older than age 50 years would mainly be
due to age, and hence, the impact of HCMV replication would
be less.
We also observed that in the absence of HCMV replication,
there was a linear correlation between increased age and the
loss of CD28 expression by both HCMV-specific and total
CD8 T cells, as previously stated by other authors (27, 29, 50).
However, this correlation was not observed in patients with
viral replication, and all patients from the youngest to the
oldest (older than age 70 years of age) had a high percentage
of CD28 cells in the pool of HCMV-specific CD8 T cells but
not in total CD8 T cells. Multivariate linear regression anal-
ysis also supports the association of HCMV replication and age
with the percentage of CD28 HCMV pentamer-positive CD8
T cells, whereas no association with donor-recipient HCMV
serostatus or the type of organ transplanted was found. This
was confirmed when patients were analyzed by age, as HCMV
replication in younger patients (those younger than age 50
years) was associated with an increased percentage of CD28
HCMV-specific CD8 T cells, which was similar to that
observed in patients older than age 50 years without viral
replication, whose percentage of CD28 cells is likely to be
increased with age. Similar results have been published by
other authors, who showed that active HCMV infection in
kidney (16) and lung (52) transplant recipients increases the
frequency of CD28 expression in CD8 T cells. Therefore,
the decreased frequency of CD28 expression observed in
younger patients with HCMV replication could be the result of
the activation of T cells by interaction with the virus (3, 16, 17,
48). Furthermore, the fact that this association was observed
only in the HCMV-specific T-cell population (and not in the
total T-cell population) would support the idea of its relation-
ship to viral replication. This replicative pressure would lead
naïve CD28 T cells in patients younger than age 50 years to
become memory cells and eventually CD28 effector cells
which might show characteristics of senescent cells (17, 44) and
certain similarities to CD28 cells in older patients. This might
partly explain the fact that HCMV replication was associated
with a decrease in the percentage of naïve-phenotype cells
(CD45RA CCR7) and early-phenotype cells (CD27
CD28) and an increase in the percentage of intermediate-
phenotype cells (CD27 CD28) (3).
This downregulation of CD28 cells has been described
under conditions that cause chronic immune stimulation, such
as inflammatory diseases (20, 35), cancer (6, 7, 11, 30, 40), and
other latent viral infections, such as infection with human im-
munodeficiency virus (HIV) or Epstein-Barr virus (3, 48).
Therefore, even though all patients with viral replication in-
cluded in our study had a high percentage of CD27 or CD28
cells in the HCMV-specific T-cell population, this subpopula-
tion might have distinct functions, depending on the length of
contact with the virus. In this regard, it has been reported that
CD28 cells from younger persons are mostly CD45RA,
while those from elderly persons are usually CD45RA, which
seem to be truly senescent cells (2). The latter cells are char-
acterized by their high degree of differentiation, which is
higher than that of CD8 T-cell populations specific to other
persistent viruses such as HIV and Epstein-Barr virus (3, 8, 39,
48). They also show a series of alterations that lead to a state
of clonal exhaustion or replicative senescence, characterized by
phenotypic and functional changes (12, 18, 22, 43, 49), which in
turn lead to decreased levels of secretion of gamma interferon
(2, 37, 38, 42), perforin, and granzymes, making them more
inefficient for cytotoxicity than CD45RA cells (4, 54). In
addition, these exhausted clones resemble in some aspects the
senescent clones that naturally accumulate throughout aging
(5, 29, 47, 50), and age and latent HCMV infection seem to
induce similar changes in the T-cell pool (51). Further studies
are therefore necessary to clarify this aspect in transplant pa-
tients with prior HCMV replication. The importance of clari-
fying the functionality of the CD27/CD28 HCMV-specific
T-cell population lies in the possible consequences that it may
have on the incidence of certain posttransplantation diseases,
such as rejection (25, 52), the development of other infections
(including the new replication of HCMV or other herpesvi-
ruses), tumor development, posttransplantation vasculopathy,
diabetes, and even mortality (15, 31). An illustrative case
would be HIV infection, in which the accumulation of virus-
specific clones with features of replicative senescence has been
correlated with disease progression (28).
Although we cannot rule out the possibility that our results
for patients younger than age 50 years were merely the conse-
quence of stimulation of the immune system by HCMV in
immunosuppressed patients, other hypotheses can also be pro-
posed. The first is that the increase in the frequency of expres-
sion of CD27/CD28 HCMV-specific CD8 T cells in
younger transplant recipients corresponds to a form of accel-
erated immune senescence at early ages associated, among
other possible factors, with HCMV replication (5, 17, 45).
Another alternative hypothesis would be that phenotypic
changes are generated before or during transplantation (dur-
ing which the patient receives dialysis, immunosuppressants,
etc.), which may facilitate viral replication. Clarification of the
factors involved would require a prospective cohort study to be
conducted with patients with and without HCMV replication
with the aim of studying the phenotypic and functional changes
from before to different points after transplantation.
In conclusion, our study shows that in transplant recipients,
HCMV replication is associated with an increased frequency
of CD27/CD28 HCMV-specific CD8 T cells in patients
1436 CANTISÁN ET AL. CLIN. VACCINE IMMUNOL.
younger than age 50 years, so the proportion of these subpopu-
lations observed in patients younger than age 50 years is similar
to that observed in patients older than age 50 years without
HCMV replication. HCMV replication may cause phenotypic
changes in younger transplant recipients similar to those in-
duced by age. Further studies are necessary to clarify the func-
tional changes associated with these phenotypic changes and
their potential relationship to clinical complications posttrans-
plantation.
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